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Introduction
Prion diseases,1 originally called transmissible spongiform 
encephalopathies,2 are invariably fatal neurodegenerative dis-
eases that affect humans and animals. The key characteristics 
of human spongiform encephalopathies are (1) heterogeneity of 
the clinical and pathologic phenotype,3-5 (2) a single pathologic 
process, which may present as a sporadic, genetic or infectious 
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The yeast, fungal and mammalian prions determine 
heritable and infectious traits that are encoded in alternative 
conformations of proteins. They cause lethal sporadic, familial 
and infectious neurodegenerative conditions in man, including 
Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-
Scheinker syndrome (GSS), kuru, sporadic fatal insomnia (SFi) 
and likely variable protease-sensitive prionopathy (vPSPr). The 
most prevalent of human prion diseases is sporadic (s)CJD. 
Recent advances in amplification and detection of prions led 
to considerable optimism that early and possibly preclinical 
diagnosis and therapy might become a reality. Although 
several drugs have already been tested in small numbers of 
sCJD patients, there is no clear evidence of any agent’s efficacy. 
Therefore, it remains crucial to determine the full spectrum 
of sCJD prion strains and the conformational features in the 
pathogenic human prion protein governing replication of sCJD 
prions. Research in this direction is essential for the rational 
development of diagnostic as well as therapeutic strategies. 
Moreover, there is growing recognition that fundamental 
processes involved in human prion propagation—intercellular 
induction of protein misfolding and seeded aggregation of 
misfolded host proteins—are of far wider significance. This 
insight leads to new avenues of research in the ever-widening 
spectrum of age-related human neurodegenerative diseases 
that are caused by protein misfolding and that pose a major 
challenge for healthcare.
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illness,6 and (3) the age dependence of genetic as well as sporadic 
forms—the annual peak incidence is 3–6 cases per million peo-
ple between 65 and 79 years of age.6,7 Despite their rarity, human 
prion diseases have gained considerable importance because their 
unique etiology and pathogenesis challenged basic principles of 
biology. Furthermore, prion diseases can be transmitted between 
humans as well as from animals to humans by an agent that is 
highly resistant to inactivation and which thus poses novel prob-
lems to disease control and public health. Finally, because of the 
marked heterogeneity of their clinical phenotype, prion diseases 
are difficult to differentiate from other age-related brain neuro-
degenerations, a feature that has prompted the establishment of 
specialized prion disease surveillance centers worldwide. Human 
prion diseases also include inherited forms as well as forms 
acquired by infection (Table 1). However, this review focuses on 
the molecular aspects of the pathogenesis of sporadic forms.
From Slow Virus to the Prion Concept
Sporadic Creutzfeldt-Jakob disease (sCJD) is the most common 
form of human spongiform encephalopathy, accounting for ~85% 
of all human prion disease.8 The term “Creutzfeldt-Jakob dis-
ease” (CJD) was introduced by Alfons Maria Jakob in 1921, who 
referred to a previous case described by Hans Gerhard Creutzfeldt 
in 1920.9,10 These original cases were clinically heterogeneous and 
neuropathologic review of the historical material with modern 
tools provided confirmation of the diagnosis of CJD in only two 
of the original five cases.11 Over the next two decades, the clini-
copathological classification of CJD remained uncertain and for 
example Wilson concluded that CJD is a “dumping ground for 
several rare cases of presenile dementia.”12 Although monograph 
by Kirschbaum13 listed the clinical and pathologic characteristics 
of 150 cases diagnosed before 1965, it included also cases such as 
Creutzfeldt’s original case, which would not fulfill criteria for the 
diagnosis of CJD today. Importantly, in the 1960s, Nevin and 
Jones described the typical clinical symptoms, electroencepha-
logram (EEG) and neuropathologic changes, including spongi-
form change, which together are now recognized as the paradigm © 2012 Landes Bioscience.
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to which the infectious pathogen responsible for human prion 
diseases is an abnormal protein, designated PrPSc.1
The discovery that proteins could be infectious represented 
a new paradigm of molecular biology and medicine. Although 
originally deemed heretical, this protein-only model is now sup-
ported by a wealth of biochemical, genetic and animal stud-
ies.6,35-38 Moreover, the concept of prion diseases has important 
implications for other neurodegenerative disorders. Recent stud-
ies with amyloid β, tau, α-synuclein, huntingtin and superox-
ide dismutase 1 suggest that molecular and cellular mechanims 
that were first discovered in studies of prions are involved in the 
pathogenesis of other neurodegenerative disorders associated with 
the accumulation of misfolded proteins, including Parkinsonism, 
Huntington disease, amyotrophic lateral sclerosis (ALS) and 
Alzheimer disease.39-43
Pathogenetic Mechanisms  
of Human Sporadic Prion Diseases
The basic event shared by all three forms of prion diseases—spo-
radic, inherited and acquired by infection—is a change in con-
formation of the normal or cellular PrP (PrPC) which is converted 
into a pathogenic PrP isoform commonly identified as PrPSc for 
prototypic scrapie (Sc) PrP.1 Human PrPC is encoded by the PrP 
gene (PRNP) on chromosome 20 and expressed at different 
levels in most mammalian cells. It comprises 209 amino acids 
(23–231), two sites of N-linked glycosylation, a disulfide bond 
and a glycolipid anchor.44-49 The variable degree of glycosylation 
is responsible for the presence of di-, mono- and un-glycosyl-
ated forms of PrPC. Because of the glycolipid anchor, most of 
the PrPC is extracellularly linked in specialized cholesterol-rich 
domains (caveoli) of the cell plasma membrane.48,50 In normal 
conformation, human PrPC comprises a C-terminal globular 
domain (involving residues 127–231), which consists of three 
α-helices and two short β-sheets.51 In contrast, the N-terminus 
is unstructured.51
The PrPSc, in contrast, is pathogenic, infectious and displays 
different biophysical features, forming insoluble aggregates of 
different sizes with predominantly β-sheet secondary struc-
ture; the C-terminal region is relatively resistant to proteolytic 
degradation.52-54 The conformational transition that underlies 
these pronounced changes is believed to involve refolding of the 
features of sporadic CJD.14 Subsequently, new sporadic forms of 
the spongiform encephalopathies with unique phenotypic fea-
tures were described; specifically, sporadic fatal insomnia (SFI) 
in 1997,15,16 and the latest likely new candidate, variable protease-
sensitive prionopathy (VPSPr) in 2008.17
Controversy concerning the cause of human spongiform 
encephalopathies has polarized the scientific community for 
decades. The 1950s saw considerable interest in an epidemic of 
a neurodegenerative disease, kuru, characterized principally by 
a progressive cerebellar ataxia, among the Fore people of the 
Eastern Highlands of Papua New Guinea.18,19 Fieldwork by 
Carleton Gajdusek and Vincent Zigas suggested that kuru was 
transmitted during cannibalistic feasts.20 Importantly, in 1959 
Hadlow pointed out the similarities between kuru and scrapie 
of sheep at the neuropathologic and clinical levels and suggested 
that human diseases might also be transmissible.21 Subsequent 
transmission of kuru (in 1966) and then CJD (in 1968) by intra-
cerebral inoculation of brain homogenates into chimpanzees, 
work which was conducted by Gajdusek, Gibbs and colleagues, 
was a landmark discovery which led to the concept of the “trans-
missible spongiform encephalopathies.”22,23 The transmission 
of Gerstmann-Sträussler-Scheinker disease (GSS) followed in 
198124 and fatal familial insomnia (FFI) in 1995.25 Interestingly, 
Jakob, suspecting in his original observations that the condition 
might be transmissible, inoculated rabbits experimentally, in an 
attempt to demonstrate this in the 1920s.26 However, thanks to 
the important role of serendipity in science, his experiment was 
unsuccessful and we know now that rabbits are uniquely resistant 
to prion infections.27
The transmission of CJD and of kuru allowed refinement of 
the diagnostic pathologic criteria for human spongiform enceph-
alopathy and led to the conclusion that all the human conditions 
share common histopathologic features: spongiform vacuola-
tion (affecting any part of the cerebral gray matter), neuronal 
loss and astrocytic proliferation that may be accompanied by 
amyloid plaques.28-31 One analogy with scrapie in sheep, it was 
assumed that the causative agent must be some type of atypi-
cal “slow virus,” the term Sigurdsson coined in 1954 for scrapie 
infection.2,32 Regrettably, despite extensive efforts in Europe and 
the US, no non-host DNA or RNA could be found, and a grow-
ing body of data pointed to a causative agent having unique char-
acteristics.33,34 Most researchers today accept the model according 
Table 1. etiologic classification of human prion diseases
Etiology Mechanism Disease
Sporadic Somatic mutation or spontaneous conversion of PrPC into PrPSc? Sporadic Creutzfeldt-Jakob disease
Somatic mutation or spontaneous conversion of PrPC into PrPSc? Sporadic fatal insomnia
Unknown variable protease-sensitive prionopathy
Hereditary Germ-line mutations in the PRnP gene Familial Creutzfeldt-Jakob disease
Germ-line mutations in the PRnP gene Fatal familial insomnia
Germ-line mutations in the PRnP gene Gerstmann-Sträussler-Scheinker disease
Acquired infection through ritualistic cannibalism Kuru
Zoonotic infection with bovine prions variant Creutzfeldt-Jakob disease
infection from prion-contaminated human growth hormone, dura mater grafts, etc. iatrogenic Creutzfeldt-Jakob disease© 2012 Landes Bioscience.
Do not distribute.
110  Prion  volume 6 issue 2
laboratory rodent prion strains, in which the digestion of brain 
PrPSc with proteolytic enzyme proteinase K (PK) consistently 
results in a single protease-resistant domain with mass ~19 kDa, 
the outcome in sCJD is more complex. Distinctive glycosylation 
patterns and up to four PK-resistant fragments of the pathogenic 
prion protein (rPrPSc) found in sCJD brains are easily distin-
guishable on western blot (WB).5,71,74-77
The WB findings together with human PRNP gene poly-
morphism led Parchi, Gambetti and colleagues to posit a clini-
copathological classification of sCJD into five or six subtypes; 
notably, the WB characteristics of PrPSc breed true upon trans-
mission to susceptible transgenic mice and Guinea pigs (Cavia 
porcellus).5,71,74,78 An alternative classification of the PrPSc types 
and their pairing with CJD phenotypes has been proposed by 
Collinge and collaborators.37,75,76,79 This classification differs 
from the previous one in two major aspects: first, it recognizes 
three (not two) PrPSc electrophoretic mobilities and second, it 
also identifies PrPSc isoforms with different ratios of the three 
PrP glycoforms.37 Although the disease phenotypes of patients 
with sCJD are remarkably heterogeneous, 21 kDa fragments of 
unglycosylated PrPSc (Type 1) frequently differ from the disease 
duration and phenotypes associated with the 19 kDa fragments 
of unglycosylated PrPSc (Type 2).3,5,71,74
Cumulatively, these findings argue that the PrPSc type repre-
sents yet an additional major modifier of the phenotype in human 
prion diseases; accordingly, WB-based clinicopathologic classifi-
cations became an important tool in studies of prion pathogenesis 
in human brains and in transgenic mice models.37,71 Because two 
distinct PK cleavage sites in PrPSc Types 1 and 2 most likely stem 
from distinct conformations, some investigators contend that 
PrPSc Types 1 and 2 code distinct prion strains.3,71,75,80 However, 
the heterogeneity of sCJD, along with a growing number of stud-
ies including bioassays, all suggest that the range of prions caus-
ing sCJD exceeds the number of categories recognized within the 
current WB-based clinicopathologic schemes.81-83 Additionally, 
recent findings of the co-occurrence of PrPSc Types 1 and 2 in 
40% or more sCJD cases created a conundrum and suggested 
that the originally observed differences were quantitative rather 
than qualitative.84-89 Finally, up to 90% of brain PrPSc in sCJD 
eludes WB analysis because it is destroyed by proteinase-K treat-
ment, which is necessary to eliminate PrPC.81 Consequently, the 
conformation or role of this major protease-sensitive (s) fraction 
of PrPSc in the pathogenesis of the disease is a subject of specula-
tion.64,81,90 Thus, no direct structural data are available for sCJD 
brain PrPSc beyond the evidence that it is resistant to proteolytic 
digestion. Nevertheless, to determine the full spectrum of sCJD 
prion strains, and the conformational features in the pathogenic 
human prion protein governing replication of sCJD prions is fun-
damental for the rational development of diagnostic as well as 
therapeutic strategies.
Novel Conformational Methods Derived from  
a Conformation-dependent Immunoassay (CDI)
Three obstacles have slowed progress in the research of human 
prions: phenotypic variability of sCJD on complex genetic 
C-terminal region whereby the α-helical structures of PrPC are 
replaced by β-sheet to different extents and with variable pat-
terns.55 Although insolubility and protease resistance were the 
original defining features of PrPSc, the finding of protease-sensi-
tive small oligomers of pathogenic PrPSc 56,57 significantly broad-
ened the spectrum of pathogenic conformers.
Although some authors believe that the toxicity in prion dis-
ease can be explained as a loss of function of PrPC due to the 
conformational transformation,58 others argue that a gain of toxic 
function is more likely.59,60 Nevertheless, there is general agree-
ment that PrPC serves as a substrate for conversion to PrPSc and 
as a major receptor for toxic effects of PrPSc. Thus the neuropro-
tective function physiologically provided by PrPC could be lost 
following its conversion to PrPSc. The prevailing presence of PrPSc 
on neuronal plasma membrane also at the synapse might explain 
the widespread spongiform degeneration, which can be viewed 
as intracellular edema. All these changes are pathognomonic of 
sCJD. Apoptosis and oxidative stress are reported to occur when 
PrPSc aggregates form at the cell surface and may well contribute 
to the neuronal cell loss that is prominent in prion diseases of 
long duration and in prion diseases like SFI, which manifest no or 
minimal spongiosis as well as severe neuronal loss.61 Astrogliosis, 
a common reaction to injury, is considered a secondary response.
The Origin and Phenotypic Heterogeneity of sCJD
Several explanations have been proposed for the etiology of spo-
radic prion diseases. These include spontaneous somatic muta-
tions in the PRNP gene or rare stochastic conformational changes 
in the structure of PrPC.62 These explanations presuppose that the 
mutant PrPSc would have to be capable of recruiting wild-type 
PrPC; however, this process which might occur with some muta-
tions or conformations but is unlikely with others.63 According to 
a second explanation, low amounts of PrPSc-like isoforms are nor-
mally present in brain, and possibly bound to other proteins such 
as heat shock proteins, however, this protective mechanism fails 
with aging.64,65 Finally, it has been suggested that at least some 
cases of apparent sCJD result from covert, low-level exposure to a 
“common external factor.”66
With more cases investigated after the original reports by 
Jakob, it became clear that the clinical as well as histopatho-
logic features of sCJD are remarkably diverse, perhaps making 
the human prion diseases the most heterogeneous of all neuro-
degenerative disease. On the basis of predominant clinical and 
pathologic features, the following phenotypic subtypes of sCJD 
were proposed in the 1980s: (1) myoclonic or cortico-striatal-
spinal, (2) amaurotic or Heidenhain, (3) classical or diffuse, 
(4) thalamic, (5) ataxic or cerebellar and (6) amyotrophic.67-69 
Researchers today generally agree that the genotype at codon 
129 of the chromosomal gene PRNP, and to some degree the 
phenotypes of these diseases, underlie susceptibility to prion dis-
eases.5 Additionally, many lines of evidence from experiments 
with laboratory prion strains support the view that the phenotype 
of sCJD—its distinctive incubation time, clinical features and 
brain pathology—is enciphered in the strain-specific conforma-
tion of PrPSc.56,70-73 However, in contrast to the experiments with © 2012 Landes Bioscience.
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protease-sensitive oligomers and intermediates of PrPSc cannot 
be obtained with WB techniques and may explain some mark-
edly different values.102
Structural Heterogeneity of sCJD PrPSc  
and the Role of sPrPSc in Pathogenesis
Our recent finding of 6-fold difference in concentrations of PrPSc 
between Type 1 and Type 2 PrPSc (129M) in the frontal cortex 
was surprising, even though some variability was to be expected 
due to differences in the predominantly affected areas in distinct 
sCJD phenotypes.81,92 Moreover, the average levels of PrPSc were 
up to 100-fold lower than those in standard laboratory prion 
models such as Syrian hamsters infected with Sc237 prions;56 
and together with the up to 100-fold variability within each phe-
notypic group, these lower levels of PrPSc may explain why some 
sCJD cases are difficult to transmit, and why lower endpoint 
titers are obtained with human prions in transgenic mice express-
ing human or chimeric PrPC.37,71,81,103
Up to 90% of the pathogenic prion protein in sCJD is prote-
ase-sensitive81 and we found the highest concentrations in Type 2 
PrPSc (129M) (Fig. 1).92 The broad range of absolute and relative 
levels of rPrPSc and sPrPSc offers evidence of a broad spectrum 
of PrPSc molecules differing in protease sensitivity in each group 
with an identical polymorphism at codon 129 of the PRNP gene 
and an identical WB pattern. Moreover, these findings signal the 
existence of a variety of sCJD PrPSc conformers; and since prote-
ase sensitivity is one of the characteristics of prion strains, they 
also suggest that distinct sCJD prion strains exist.56,57,81,82,104,105
The heterogeneity of PrPSc conformations we found with CDI 
within sCJD patients homozygous for codon 129 plymorphism 
of the PRNP gene is remarkable, having a range corresponding 
to that of stabilities found in approximately 30 distinct strains 
of de-novo and natural laboratory rodent prions studied up to 
now.56,72,92,106 The intriguing differential effect of PK treatment 
background, biosafety constraints, and lack of 
suitable tools for studying molecular character-
istics beyond WB typing. Aiming to advance 
our understanding of the molecular pathogen-
esis of human prion diseases, we developed 
the conformation-dependent immunoassay 
(CDI),56,81,91 to determine the conforma-
tional range and strain-dependent molecular 
features of sCJD PrPSc, first in patients who 
were homozygous for codon 129 of the PRNP 
gene.92 Even relatively minute variations in a 
soluble protein structure can be determined by 
measuring conformational stability in a dena-
turant such as Gdn HCl.93 Utilizing this con-
cept, we designed a procedure in which PrPSc is 
first exposed to denaturant Gdn HCl and then 
exposed to europium-labeled mAb against the 
epitopes hidden in the native conformation.56 
As the concentration of Gdn HCl increases, 
PrPSc dissociates and unfolds from native 
β-sheet-structured aggregates, and more 
epitopes become available to antibody binding. These experi-
ments involve insoluble oligomeric forms of PrPSc, and dena-
turation of this protein is irreversible in vitro; consequently the 
Gibbs free energy change (ΔG) of PrPSc cannot be calculated.94 
Therefore we chose instead to use the Gdn HCl value found at 
the half-maximal denaturation ([GdnHCl]1/2) as a measure of 
the relative conformational stability of PrPSc. The differences in 
stability reveal evidence of distinct conformations of PrPSc.56,93,94
To measure the concentration of different forms of PrPSc and 
follow the unfolding, we used europium-labeled mAb 3F495 
(epitope residues 107–112) for detection and 8H4 mAb (epit-
ope residues 175–185),96 to capture human PrPSc in a sandwich 
CDI format.81,97 The analytical sensitivity and specificity of the 
optimized CDI for detection of PrPSc was previously reported 
by us and others in numerous publications56,81,91,98-100 and has 
been shown to be as low as ~500 fg (~20 attomoles) of PrPSc 
which is similar to the sensitivity of human prion bioassay in 
Tg(MHu2M)5378/Prnp0/0 mice.81 Because CDI is not depen-
dent on protease treatment, it allowed us to address fundamen-
tal questions concerning the concentration and conformation of 
different isoforms of sCJD PrPSc, including protease-sensitive (s) 
and protease-resistant (r)PrPSc.92
The dissociation and unfolding of PrPSc in the presence of 
increasing concentration of Gdn HCl can be described as follows:
[PrPSc]n →[sPrPSc]n → iPrP → uPrP
where [PrPSc]n are native aggregates of PrPSc, [sPrPSc]n are soluble 
protease-sensitive oligomers of PrPSc, iPrP is an intermediate, 
and uPrP is completely unfolded (denatured) PrP.53,57,94 The 
CDI monitors the global transition from native aggregates to 
fully denatured monomers of PrPSc. In contrast, the WB-based 
techniques monitor either the partial solubilization of PrPSc 101 
or conversion of rPrPSc to protease-sensitive conformers72 after 
exposure to denaturant. As a result, the stability data on soluble 
Figure 1. The relationship between duration of the disease, (left part) concentration and 
(right part) conformational stability of sPrPSc conformers in sCJD patients with different 
wB patterns and PRnP gene polymorphisms.92 The stability of PrPSc was determined with 
CDi before and after protease treatment and the change is expressed as ΔGdn HCl1/2.92 The 
symbols are mean ± SeM in each sCJD group.© 2012 Landes Bioscience.
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jointly represent an important parameter, which is influenced 
by replication rate, propagation and clearance of prions from 
the brain.64,109 The correlations among the levels of sPrPSc, the 
stability of sPrPSc, and the duration of the disease found in this 
study all indicate that sPrPSc conformers play an important role 
in the pathogenesis. When sPrPSc is less stable than rPrPSc, the 
difference in stability correlates with less accumulated sPrPSc and 
shorter duration of the disease. Conversely, when sPrP conform-
ers are more stable than rPrPSc, we observed the opposite effect—
more accumulated sPrPSc and extended disease duration (Fig. 1).
In laboratory rodent prion models, we found that levels of 
sPrPSc varied with the incubation time of the disease56 and we 
hypothesized that the molecular mechanism of this link may be 
related to the replication or clearance rate of prions.56,64,81 Our 
recent data on sCJD prions extend this observation and indicate 
that higher levels of less stable sPrPSc lead to faster progression of 
the disease.92 These observations are in accord with the experi-
ments on yeast prions and suggest that the stability of misfolded 
protein is inversely related to the replication rate.110 Although the 
modulating effect of prion clearance in the mammalian brains is 
likely,64 the data from both yeast and human prions lead to the 
hypothesis that the less stable prions replicate faster by exposing 
more available sites for growth of the aggregates. In mammalian 
prions, this effect leads to shorter incubation time and faster pro-
gression of the disease.
Future Directions
Additional steps are necessary to improve our understanding 
of the phenotypic diversity of sCJD. One step is to determine 
whether the mixed WB patterns of Type 1–2 rPrPSc in the same 
or different anatomical areas represent a unique conformation or 
a mixture of conformers, and to map the distribution in the indi-
vidual brain.89 Additionally, novel conformational approaches 
using tandem protein misfolding cyclic amplification (PMCA) 
and CDI should allow analysis of the impact of different PrPSc 
polymorphisms and conformations on the replication rate of 
human prions. Such studies have clearly broader implications, 
as recent data suggest that the process of intercellular induction 
of protein misfolding is relevant in the pathogenesis of growing 
number of other neurodegenerative diseases.39-43
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with increasing stability of Type 1 and decreasing stability of 
Type 2 PrPSc (129M) suggests that in contrast to Type 1, the 
protease-resistant core of Type 2 was profoundly destabilized. 
Together with the increased frequency of exposed epitopes in 
codon 129 MM samples with Type 2 rPrPSc after PK treatment, 
these observations may indicate one of three possibilities: that 
the ligand protecting the 3F4 epitope was removed by PK treat-
ment; that epitope 108–112 was protected by the N-terminus of 
PrPSc; or that conformational transition resulted in more exposed 
108–112 epitope. Whether the epitope hindrance in undigested 
PrPSc is the result of lipid, glycosaminoglycan, nucleic acid or pro-
tein binding to the conformers unique to the MM2 sCJDF PrPSc 
remains to be established. Since sCJD cases with Type 2 PrPSc 
(129M) have remarkably extended disease durations, the molecu-
lar mechanism underlying these effects calls for detailed inves-
tigation. Cumulatively, our findings indicate that sCJD PrPSc 
exhibits extensive conformational heterogeneity and suggest that 
a wide spectrum of sCJD prions cause the disease. Whether this 
heterogeneity originates in a stochastic misfolding process that 
generates many distinct self-replicating conformations37,62 or in a 
complex process of evolutionary selection during development of 
the disease73 remains to be established.
We discovered protease-sensitive conformers of PrPSc while 
developing a conformation-dependent immunoassay (CDI), 
which does not require proteolytic degradation of ubiquitous 
PrPC.56 Although the original definition of sPrPSc was purely 
operational, considerable additional data demonstrate that 
(1) sPrPSc replicates in vivo and in vitro as an invariant and 
major fraction of PrPSc; (2) sPrPSc separates from rPrPSc in high 
speed centrifugation and (3) the proteolytic sensitivity of PrPSc 
can reliably differentiate various prion strains.56,57,81,82,104,105 
Accumulation of sPrPSc precedes protease-resistant product 
(rPrPSc) in prion infection,64,107 and up to 90% of PrPSc accumu-
lating in CJD brains consists of sPrPSc.81 Thus, the detection by 
CDI of sPrPSc as a disease-specific marker is widely regarded as a 
more reliable basis for diagnosing prion diseases. This improved 
detection led to the discovery of a new human prion disorder, 
variably protease-sensitive prionopathy (VPSPr).17,56,81,90,108 It 
is noteworthy that synthetic prions generated in vitro during 
polymerization of recombinant mouse PrP into amyloid fibers 
produced prions composed exclusively of sPrPSc upon inocula-
tion into wild mice.106
Our recent data indicate that the levels as well as stability 
of sPrPSc are a good predictor of the progression rate in sCJD 
(Fig. 1).92 Despite the inevitable influence of variable genetic 
background and the potential difficulties in evaluating initial 
symptoms, the disease progression rate and incubation time 
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